NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Open in Screener

OABI

OmniAb Inc

Jul 11 • 04:00PM ET

2.03

Dollar change -0.03
Percentage change -1.46	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX ONC EBS FOLD KURA MGNX ADAP XBIT ONCT

| Held by: IWM VTI VXF IWN SCHA DFAT VTWO DFAS IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-0.59	Insider Own	24.76%	Shs Outstand	122.13M	Perf Week	5.18%
Market Cap	248.34M	Forward P/E	-	EPS next Y	-0.45	Insider Trans	0.21%	Shs Float	91.05M	Perf Month	31.82%
Enterprise Value	227.23M	PEG	-	EPS next Q	-0.15	Inst Own	55.27%	Short Float	9.16%	Perf Quarter	1.50%
Income	-61.27M	P/S	9.29	EPS this Y	3.07%	Inst Trans	-2.94%	Short Ratio	7.98	Perf Half Y	-44.23%
Sales	26.74M	P/B	0.91	EPS next Y	23.17%	ROA	-18.60%	Short Interest	8.34M	Perf YTD	-42.66%
Book/sh	2.24	P/C	5.70	EPS next 5Y	21.29%	ROE	-21.32%	52W High	4.96 -59.07%	Perf Year	-49.75%
Cash/sh	0.36	P/FCF	-	EPS past 3/5Y	-22.79% -	ROIC	-20.97%	52W Low	1.22 66.39%	Perf 3Y	-79.81%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.76% -	Gross Margin	22.69%	Volatility	10.06% 7.24%	Perf 5Y	-
Dividend TTM	-	EV/Sales	8.50	EPS Y/Y TTM	6.74%	Oper. Margin	-266.93%	ATR (14)	0.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.70	Sales Y/Y TTM	27.07%	Profit Margin	-229.11%	RSI (14)	63.26	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.70	EPS Q/Q	8.45%	SMA20	12.62%	Beta	0.17	Target Price	8.25
Payout	-	Debt/Eq	0.08	Sales Q/Q	9.29%	SMA50	25.79%	Rel Volume	0.71	Prev Close	2.06
Employees	114	LT Debt/Eq	0.07	Earnings	May 08 AMC	SMA200	-31.70%	Avg Volume	1.04M	Price	2.03
IPO	Sep 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.79% -7.45%	Trades		Volume	746,291	Change	-1.46%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$6
Apr-21-23	Initiated	The Benchmark Company	Buy	$8
Apr-13-23	Initiated	Craig Hallum	Buy	$10
Feb-22-23	Initiated	Cowen	Outperform	$10
Feb-13-23	Initiated	H.C. Wainwright	Buy	$11
Dec-20-22	Initiated	Truist	Buy	$10
Dec-16-22	Initiated	Credit Suisse	Outperform	$13
Nov-29-22	Initiated	SVB Leerink	Outperform	$6
Nov-28-22	Initiated	Stifel	Buy	$12

Jun-30-25 09:50AM	AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway (PR Newswire)
May-13-25 04:05PM	OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration Platform at the 21st Annual PEGS Boston Summit (Business Wire) +8.57%
May-09-25 08:31AM	Is OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey) -8.28%
May-08-25 05:40PM	OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:06PM	OmniAb Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
04:05PM	Loading…
04:05PM	OmniAb Introduces the xPloration® Partner Access Program (Business Wire)
May-05-25 12:59PM	VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program (GlobeNewswire)
May-01-25 08:00AM	OmniAb to Participate in Five Upcoming Investor Conferences (Business Wire)
Apr-21-25 08:00AM	OmniAb Announces Two New Appointments to its Board of Directors (Business Wire)
Apr-14-25 08:00AM	OmniAb to Report First Quarter 2025 Financial Results on May 8 (Business Wire)
Mar-18-25 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (Business Wire) -20.38%
Feb-24-25 08:00AM	OmniAb to Report Fourth Quarter 2024 Financial Results on March 18 (Business Wire)
Feb-03-25 04:57PM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-16-24 04:15PM	OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering and Therapeutics Conference (Business Wire)
Nov-12-24 04:05PM	OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire) -9.35%
08:00AM	Loading…
Oct-30-24 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Oct-22-24 08:00AM	OmniAb to Report Third Quarter 2024 Financial Results on November 12 (Business Wire)
Aug-26-24 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-08-24 04:05PM	OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire) +5.67%
Jul-25-24 08:00AM	OmniAb to Report Second Quarter 2024 Financial Results on August 8 (Business Wire)
Jun-03-24 04:05PM	OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology (Business Wire)
May-20-24 08:05AM	OmniAb to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-15-24 04:05PM	OmniAb Presents High-Throughput Single B-cell Screening xPloration Data at the 20th Annual PEGS Boston Summit (Business Wire)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-09-24 08:56PM	OABI Stock Earnings: OmniAb Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	OmniAb Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
May-01-24 08:00AM	OmniAb to Participate in Five Investor Conferences in May (Business Wire)
Apr-22-24 08:00AM	OmniAb to Report First Quarter 2024 Financial Results on May 9 (Business Wire)
Mar-21-24 11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.17%
Mar-20-24 08:54PM	OABI Stock Earnings: OmniAb Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:05PM	Loading…
04:05PM	OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Feb-28-24 08:27AM	OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock? (Zacks)
Feb-26-24 08:00AM	OmniAb to Report Fourth Quarter 2023 Financial Results on March 20 (Business Wire)
Feb-20-24 08:00AM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-14-23 04:30PM	OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference (Business Wire)
Nov-20-23 12:39PM	OmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 05:03AM	Insider Buying: OmniAb Inc CEO Matthew Foehr Acquires 95,000 Shares (GuruFocus.com) +6.32%
Nov-09-23 05:55PM	OmniAb Highlights OmnidAb Launch and its Expanding Drug Discovery Platform at Todays Research & Technology Virtual Event (Business Wire)
09:24AM	OmniAb Inc (OABI) Reports Decline in Q3 Revenue and Widening Net Loss (GuruFocus.com)
08:00AM	OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Nov-02-23 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Nov-01-23 09:00AM	OmniAb Appoints Steve Love to its Board of Directors (Business Wire)
Oct-31-23 04:28PM	OmniAb Announces Agenda for its Research & Technology Virtual Event (Business Wire)
Oct-26-23 02:32PM	7 of the Best Cheap Stocks to Buy Under $5 in October 2023 (InvestorPlace)
Oct-12-23 08:00AM	OmniAb to Hold Research & Technology Virtual Event on November 9 (Business Wire)
Sep-05-23 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-15-23 05:20AM	OmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-13-23 08:06AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Aug-10-23 04:05PM	OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire) -5.54%
Aug-07-23 04:05PM	OmniAb Announces the Passing of Director Sunil Patel (Business Wire)
Jul-31-23 08:00AM	OmniAb to Report Second Quarter 2023 Financial Results on August 10 (Business Wire)
Jul-17-23 07:35AM	With 60% institutional ownership, OmniAb, Inc. (NASDAQ:OABI) is a favorite amongst the big guns (Simply Wall St.)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +6.32%
May-18-23 05:09PM	7 Stocks to Buy for Their Massive Upside Potential (InvestorPlace)
May-17-23 04:05PM	OmniAb Launches OmniDeep at the PEGS Boston Conference and Expo (Business Wire)
May-16-23 06:06AM	President of OmniAb Matthew Foehr Buys 22% More Shares \ (Simply Wall St.) +9.12%
May-14-23 08:03AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
May-11-23 10:55PM	Q1 2023 OmniAb Inc Earnings Call (Thomson Reuters StreetEvents) +8.36%
07:00AM	OmniAb Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-05-23 07:14AM	OmniAb, Inc.'s (NASDAQ:OABI) Share Price Matching Investor Opinion (Simply Wall St.)
May-04-23 06:26AM	10 Best Small-Cap Growth Stocks to Buy Now (Insider Monkey)
May-01-23 08:00AM	OmniAb to Report First Quarter 2023 Financial Results on May 11 (Business Wire)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-25-23 08:00AM	OmniAb to Participate in Upcoming Investor Conferences in May (Business Wire)
Apr-19-23 08:30AM	Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today (Zacks)
Apr-07-23 10:24PM	OmniAb, Inc. (NASDAQ:OABI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-05-23 06:09AM	OmniAb Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Apr-02-23 08:51AM	Insiders of OmniAb, Inc. (NASDAQ:OABI) are up 11% on their US$2.3m purchase after OmniAb, Inc. (NASDAQ:OABI) rose 14% last week (Simply Wall St.)
Mar-31-23 08:40AM	Do Options Traders Know Something About OmniAb (OABI) Stock We Don't? (Zacks)
Mar-30-23 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Business Wire)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-09-23 08:00AM	OmniAb to Report Fourth Quarter 2022 Financial Results on March 30 (Business Wire) -5.03%
Mar-08-23 09:53AM	These 2 Strong Buy Penny Stocks Are Poised for a Massive Rally, Say Analysts (TipRanks)
Feb-23-23 07:49AM	Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up (Zacks)
Feb-07-23 08:00AM	OmniAb to Participate in Three Upcoming Investor Conferences (Business Wire)
Feb-01-23 06:56AM	With 44% stake, OmniAb, Inc. (NASDAQ:OABI) seems to have captured institutional investors' interest (Simply Wall St.)
Dec-16-22 12:39PM	Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says (Benzinga)
Dec-01-22 08:47AM	Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies (HSB-1940) against PD-1, by combining Quatramers with OmniAbs Picobodies, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets (GlobeNewswire) -5.37%
Nov-15-22 07:00AM	OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights (Business Wire) -10.00%
Nov-03-22 08:00AM	OmniAb to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-02-22 07:00AM	OmniAb, Inc. to Ring Nasdaq Stock Market Opening Bell (Business Wire) -60.65%
Nov-01-22 04:01PM	OmniAb Announces Completion of Spin-Off and Business Combination (Business Wire) -9.26%
04:01PM	Ligand Announces Completion of OmniAb Spin-Off (Business Wire)

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cochran Jennifer R.	Director	May 15 '25	Buy	1.52	30,000	45,600	145,274	May 15 04:02 PM
Love Steven	Director	May 14 '25	Buy	1.46	25,000	36,500	38,333	May 14 05:04 PM
HIGGINS JOHN L	Director	May 12 '25	Buy	1.44	65,000	93,600	2,831,887	May 13 05:52 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '25	Option Exercise	0.00	36,458	0	3,815,618	Apr 07 08:17 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '25	Sale	2.00	19,382	38,764	3,796,236	Apr 07 08:17 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '25	Option Exercise	0.00	13,542	0	370,418	Apr 07 08:10 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '25	Sale	2.00	7,206	14,412	363,212	Apr 07 08:10 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '25	Option Exercise	0.00	13,542	0	231,034	Apr 07 08:09 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '25	Sale	2.00	7,206	14,412	223,828	Apr 07 08:09 PM
GUSTAFSON KURT A	Officer	Apr 07 '25	Proposed Sale	2.00	7,206	14,396		Apr 07 08:04 PM
FOEHR MATTHEW W	Officer	Apr 07 '25	Proposed Sale	2.00	19,382	38,715		Apr 07 08:00 PM
Berkman Charles S	Officer	Apr 07 '25	Proposed Sale	2.00	7,206	14,396		Apr 07 07:56 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 01 '25	Option Exercise	0.00	23,244	0	229,455	Apr 01 08:43 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 01 '25	Sale	2.37	11,963	28,352	217,492	Apr 01 08:43 PM
GUSTAFSON KURT A	Officer	Apr 01 '25	Proposed Sale	2.37	11,963	28,351		Apr 01 07:16 PM
HIGGINS JOHN L	Director	Mar 21 '25	Buy	2.28	4,000	9,120	2,766,887	Mar 21 07:58 PM
HIGGINS JOHN L	Director	Mar 20 '25	Buy	2.35	125,750	295,512	2,762,887	Mar 20 08:15 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 16 '25	Option Exercise	0.00	13,541	0	213,466	Feb 19 08:51 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 19 '25	Sale	3.67	7,255	26,626	206,211	Feb 19 08:51 PM
FOEHR MATTHEW W	President and CEO	Feb 19 '25	Sale	3.67	19,522	71,646	3,779,160	Feb 19 08:51 PM
FOEHR MATTHEW W	President and CEO	Feb 18 '25	Sale	3.68	13,964	51,388	3,798,682	Feb 19 08:51 PM
Berkman Charles S	Chief Legal Officer	Feb 18 '25	Sale	3.68	8,215	30,231	364,131	Feb 19 08:50 PM
Berkman Charles S	Chief Legal Officer	Feb 19 '25	Sale	3.67	7,255	26,626	356,876	Feb 19 08:50 PM
GUSTAFSON KURT A	Officer	Feb 19 '25	Proposed Sale	3.68	5,188	19,092		Feb 18 08:36 PM
FOEHR MATTHEW W	Officer	Feb 18 '25	Proposed Sale	3.68	13,964	51,390		Feb 18 08:30 PM
Berkman Charles S	Officer	Feb 18 '25	Proposed Sale	3.68	8,215	30,232		Feb 18 08:28 PM
Berkman Charles S	Chief Legal Officer	Jan 21 '25	Sale	3.24	25,489	82,584	343,190	Jan 22 05:41 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Jan 21 '25	Sale	3.24	15,526	50,304	212,720	Jan 22 05:40 PM
FOEHR MATTHEW W	President and CEO	Jan 21 '25	Sale	3.24	41,811	135,468	3,749,639	Jan 22 05:40 PM
FOEHR MATTHEW W	Officer	Jan 21 '25	Proposed Sale	3.24	41,811	135,378		Jan 21 07:25 PM
Berkman Charles S	Officer	Jan 21 '25	Proposed Sale	3.24	25,489	82,529		Jan 21 07:24 PM
GUSTAFSON KURT A	Officer	Jan 21 '25	Proposed Sale	3.24	15,526	50,271		Jan 21 07:22 PM
Berkman Charles S	Chief Legal Officer	Dec 09 '24	Sale	4.13	8,022	33,131	323,385	Dec 10 04:47 PM
FOEHR MATTHEW W	President and CEO	Dec 09 '24	Sale	4.13	13,634	56,308	3,714,447	Dec 10 04:44 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Dec 09 '24	Sale	4.13	23,871	98,587	200,661	Dec 10 04:41 PM
GUSTAFSON KURT A	Officer	Dec 09 '24	Proposed Sale	4.13	23,871	98,476		Dec 09 08:49 PM
FOEHR MATTHEW W	Officer	Dec 09 '24	Proposed Sale	4.13	13,634	56,245		Dec 09 08:45 PM
Berkman Charles S	Officer	Dec 09 '24	Proposed Sale	4.13	8,022	33,094		Dec 09 08:41 PM
FOEHR MATTHEW W	President and CEO	Nov 25 '24	Option Exercise	3.73	99,434	370,702	3,698,600	Nov 26 04:41 PM

Dollar change -3.28
Percentage change -2.62	%

LGND Ligand Pharmaceuticals, Inc daily Stock Chart

Peers: VRTX REGN BIIB GILD INCY AMGN BMY PFE MRNA RDY

| Held by: IJR IWM VTI VB VXF VBR SPSM IWN DFAT IJT

Index	RUT	P/E	-	EPS (ttm)	-7.12	Insider Own	2.59%	Shs Outstand	19.28M	Perf Week	6.21%
Market Cap	2.35B	Forward P/E	17.41	EPS next Y	6.99	Insider Trans	0.62%	Shs Float	18.79M	Perf Month	7.30%
Enterprise Value	2.14B	PEG	-	EPS next Q	1.42	Inst Own	97.86%	Short Float	6.32%	Perf Quarter	17.19%
Income	-132.62M	P/S	12.94	EPS this Y	6.60%	Inst Trans	2.75%	Short Ratio	9.88	Perf Half Y	10.33%
Sales	181.49M	P/B	2.95	EPS next Y	14.27%	ROA	-14.58%	Short Interest	1.19M	Perf YTD	13.58%
Book/sh	41.27	P/C	11.24	EPS next 5Y	11.93%	ROE	-16.56%	52W High	129.90 -6.31%	Perf Year	32.70%
Cash/sh	10.83	P/FCF	46.52	EPS past 3/5Y	- -	ROIC	-16.60%	52W Low	90.29 34.79%	Perf 3Y	96.81%
Dividend Est.	-	EV/EBITDA	102.76	Sales past 3/5Y	-11.55% 6.80%	Gross Margin	74.61%	Volatility	3.69% 3.11%	Perf 5Y	65.70%
Dividend TTM	-	EV/Sales	11.81	EPS Y/Y TTM	-230.86%	Oper. Margin	-9.16%	ATR (14)	3.86	Perf 10Y	91.28%
Dividend Ex-Date	Jul 02, 2010	Quick Ratio	5.02	Sales Y/Y TTM	53.40%	Profit Margin	-73.07%	RSI (14)	64.60	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.27	EPS Q/Q	-146.54%	SMA20	5.17%	Beta	0.88	Target Price	143.88
Payout	-	Debt/Eq	0.01	Sales Q/Q	46.34%	SMA50	11.31%	Rel Volume	0.89	Prev Close	124.98
Employees	68	LT Debt/Eq	0.00	Earnings	May 08 BMO	SMA200	9.74%	Avg Volume	120.26K	Price	121.70
IPO	Nov 18, 1992	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.76% 17.12%	Trades		Volume	106,482	Change	-2.62%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-25	Initiated	Stifel	Buy	$143
Oct-03-24	Initiated	Oppenheimer	Outperform	$135
Jul-30-24	Initiated	RBC Capital Mkts	Outperform	$130
Apr-14-21	Resumed	Stephens	Overweight	$200
Feb-04-21	Reiterated	H.C. Wainwright	Buy	$229 → $310
Oct-06-20	Initiated	Barclays	Overweight	$156
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy	$135
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight	$110 → $132
Jun-11-19	Initiated	Barclays	Equal Weight	$131
May-03-19	Reiterated	H.C. Wainwright	Buy	$254 → $214
Mar-06-19	Reiterated	H.C. Wainwright	Buy	$281 → $254
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$270 → $280
Sep-11-18	Reiterated	Argus	Buy	$260 → $300
Aug-17-18	Initiated	Goldman	Neutral	$256
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral
Jun-21-18	Initiated	Argus	Buy	$260
Dec-27-17	Reiterated	H.C. Wainwright	Buy	$163 → $169

Show Previous Ratings

Jul-10-25 10:43AM	LGND Raises $9M to Make Earth Data Intuitive and Actionable (PR Newswire)
09:58AM	LGND wants to make ChatGPT for the Earth (TechCrunch)
08:00AM	Ligand Partner Pelthos Therapeutics Launches ZELSUVMI (GlobeNewswire)
Jul-03-25 07:17AM	Ligands LNHC concludes merger with CHRO (Pharmaceutical Technology)
Jul-02-25 07:00AM	Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement (GlobeNewswire)
07:00AM	Loading…
07:00AM	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (GlobeNewswire)
Jun-11-25 07:00AM	Ligand Announces 2025 Investor Day in New York City (GlobeNewswire)
May-14-25 07:00AM	Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 (GlobeNewswire)
May-08-25 07:44AM	Ligand Pharmaceuticals Reiterates FY25 Outlook - Update (RTT News)
07:00AM	Ligand Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:09PM	Ligand Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 07:00AM	Ligand to Participate in May Investor Conferences (GlobeNewswire)
Apr-24-25 07:00AM	Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-20-25 09:35AM	Revisiting Ligand Pharmaceuticals, Ready To Accumulate If Shares Dip Below $100 (Seeking Alpha)
06:00AM	Loading…
Apr-17-25 06:00AM	Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics (GlobeNewswire)
Apr-03-25 11:50AM	Bumbershoot Holdings 2024 Investor Letter (Seeking Alpha) -5.17%
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
07:30AM	Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-03-25 07:00AM	Ligand to Participate in March Investor Conferences (GlobeNewswire) -8.22%
Feb-27-25 07:00AM	Ligand Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 07:00AM	Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences (GlobeNewswire)
Feb-13-25 07:00AM	Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 (Business Wire)
Feb-06-25 07:00AM	Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Dec-12-24 07:45AM	Ligand price target raised to $151 from $135 at Oppenheimer (TipRanks) -5.69%
Dec-10-24 09:00AM	Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance (Business Wire)
Nov-14-24 08:00AM	Ligand to Present at Stifel 2024 Healthcare Conference (Business Wire) -5.43%
Nov-07-24 07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire) +11.12%
Nov-01-24 08:01AM	Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston (Business Wire)
Oct-23-24 04:01PM	Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
07:30AM	Loading…
Oct-17-24 07:30AM	Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer (GlobeNewswire)
Sep-06-24 09:20AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (Business Wire)
Aug-20-24 09:00AM	Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-06-24 04:01PM	Ligand Reports Second Quarter 2024 Financial Results (Business Wire) -5.78%
Jul-24-24 06:30AM	Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement (ACCESSWIRE)
Jul-23-24 04:01PM	Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 (Business Wire)
Jul-08-24 07:00AM	Ligand to Acquire APEIRON Biologics AG for $100 Million (Business Wire)
Jul-01-24 08:00AM	Lifecore Biomedical Announces Cooperation Agreement with 22NW (GlobeNewswire)
Jun-27-24 08:00AM	Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years (Business Wire) +5.80%
Jun-18-24 08:00AM	Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Adults (Business Wire)
Jun-14-24 12:00PM	What Makes Ligand (LGND) a New Strong Buy Stock (Zacks)
Jun-06-24 11:31AM	Why Is Ligand (LGND) Up 4% Since Last Earnings Report? (Zacks)
Jun-04-24 09:55AM	Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect? (Zacks) -8.05%
08:50AM	Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why (Zacks)
May-23-24 04:59PM	Ligand to Participate in Upcoming Investor Conferences (Business Wire)
May-20-24 06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-13-24 12:00PM	Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
May-10-24 08:50AM	Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-09-24 09:40AM	Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year? (Zacks) +7.17%
May-08-24 01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.75%
12:19PM	Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates (Zacks)
May-07-24 09:01PM	LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM	Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates (Zacks)
04:00PM	Ligand Reports First Quarter 2024 Financial Results (Business Wire)
11:29AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:30AM	Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement (Business Wire)
Apr-23-24 08:31AM	Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
Apr-17-24 09:55AM	Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know (Zacks)
Apr-08-24 08:15AM	Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference (Business Wire)
Apr-05-24 06:00PM	Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts (Zacks)
Apr-04-24 09:30AM	Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It? (Zacks)
09:00AM	Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know (Zacks)
Apr-03-24 09:00AM	Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI (Business Wire)
Apr-01-24 06:15PM	Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note (Zacks)
Mar-28-24 11:30AM	Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-26-24 06:15PM	Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Mar-21-24 09:00AM	Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock (Zacks)
Mar-20-24 06:00PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Mar-19-24 09:30AM	Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-14-24 06:00PM	Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors (Zacks)
Mar-07-24 09:00AM	Is Trending Stock Ligand Pharmaceuticals Incorporated (LGND) a Buy Now? (Zacks)
Mar-05-24 04:01PM	Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference (Business Wire)
Mar-04-24 08:00AM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-29-24 09:30AM	Wall Street Analysts See Ligand (LGND) as a Buy: Should You Invest? (Zacks) -5.93%
Feb-28-24 07:34AM	Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges (Zacks) -5.44%
Feb-27-24 07:00AM	Ligand Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire) +19.86%
Feb-22-24 04:01PM	Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa (Business Wire)
Feb-16-24 08:00AM	Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires (Business Wire)
Feb-13-24 04:01PM	Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (Business Wire) -6.13%
Feb-01-24 05:00PM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-10-24 07:30PM	Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene (GlobeNewswire)
Jan-05-24 04:30PM	U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum (Business Wire)
Dec-12-23 12:01PM	Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance (Business Wire)
09:00AM	Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life (GlobeNewswire)
09:00AM	Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations (GlobeNewswire)
Dec-11-23 09:00AM	Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology (GlobeNewswire)
Dec-06-23 04:02PM	Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City (Business Wire)
Dec-01-23 08:20AM	Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications (GlobeNewswire)
Nov-28-23 09:01AM	Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-09-23 04:47PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:01PM	Ligand Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-06-23 09:00AM	Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial (GlobeNewswire)
Nov-01-23 08:00AM	Ligand Acquires Royalty on Sanofis TZIELD for $20 Million (Business Wire)
Oct-25-23 04:01PM	Ligand To Report Third Quarter 2023 Financial Results On November 8 (Business Wire)
Oct-18-23 08:00AM	Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026 (GlobeNewswire)
Oct-09-23 06:15PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Oct-03-23 06:00PM	Ligand Pharmaceuticals (LGND) Stock Moves -0.71%: What You Should Know (Zacks)
Oct-02-23 09:00AM	Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer (GlobeNewswire)
09:00AM	Sermonix Pharmaceuticals Announces Results of ELAINE-1 Exploratory Analysis Evaluating Effect of Patient Characteristics on Baseline Genitourinary Symptoms (GlobeNewswire)
Sep-27-23 09:00AM	Ligand Acquires Assets of Novan, Inc. for $12.2 Million (Business Wire)

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KOZARICH JOHN W	Director	Jul 10 '25	Sale	125.00	934	116,750	46,456	Jul 11 06:17 PM
KOZARICH JOHN W	Officer	Jul 10 '25	Proposed Sale	125.00	934	116,750		Jul 10 05:08 PM
Reardon Andrew	CLO & Secretary	Jun 23 '25	Sale	114.08	500	57,042	31,903	Jun 24 08:29 PM
ANDREW THOMAS REARDON	Officer	Jun 23 '25	Proposed Sale	114.08	500	57,042		Jun 23 05:07 PM
Reardon Andrew	CLO & Secretary	Jun 10 '25	Sale	114.54	500	57,271	32,403	Jun 12 05:51 PM
ANDREW THOMAS REARDON	Officer	Jun 10 '25	Proposed Sale	114.54	500	57,271		Jun 10 06:49 PM
Reardon Andrew	CLO & Secretary	May 15 '25	Sale	104.00	1,000	104,000	32,903	Jun 02 08:06 PM
KOZARICH JOHN W	Director	Jan 17 '25	Option Exercise	52.30	2,406	125,834	46,181	Jun 02 08:05 PM
ANDREW THOMAS REARDON	Officer	May 15 '25	Proposed Sale	104.00	1,000	104,000		May 15 05:14 PM
Davis Todd C	Chief Executive Officer	May 09 '25	Buy	105.20	9,510	1,000,456	161,234	May 13 08:05 PM
Espinoza Octavio	Chief Financial Officer	May 09 '25	Buy	104.06	1,500	156,090	27,932	May 13 08:04 PM
Sabba Stephen L	Director	Apr 01 '25	Option Exercise	52.30	2,406	125,834	32,584	Apr 16 09:34 AM
Sabba Stephen L	Director	Mar 18 '25	Proposed Sale	106.00	2,406	255,036		Mar 18 04:01 PM
Espinoza Octavio	Chief Financial Officer	Mar 04 '25	Sale	115.03	5,000	575,148	18,879	Mar 06 06:55 PM
Espinoza Octavio	Officer	Mar 04 '25	Proposed Sale	115.03	5,000	575,149		Mar 04 05:10 PM
Espinoza Octavio	Chief Financial Officer	Dec 23 '24	Sale	116.37	2,104	244,850	20,647	Dec 26 08:32 PM
Espinoza Octavio	Officer	Dec 23 '24	Proposed Sale	116.37	2,104	244,851		Dec 23 08:19 PM
LAMATTINA JOHN L	Director	Nov 27 '24	Option Exercise	52.30	2,406	125,834	31,921	Dec 02 08:05 PM
LAMATTINA JOHN L	Director	Nov 27 '24	Sale	123.65	2,406	297,502	29,515	Dec 02 08:05 PM
LAMATTINA JOHN L	Director	Nov 26 '24	Proposed Sale	119.19	2,406	286,771		Nov 27 04:44 PM
Korenberg Matthew E	Officer	Nov 11 '24	Proposed Sale	120.33	32,183	3,872,684		Nov 12 10:25 AM
Reardon Andrew	CLO & Secretary	Sep 23 '24	Option Exercise	52.27	2,000	104,540	24,534	Sep 25 08:54 PM
Reardon Andrew	CLO & Secretary	Sep 23 '24	Sale	99.60	2,000	199,201	22,534	Sep 25 08:54 PM
Espinoza Octavio	Chief Financial Officer	Sep 20 '24	Sale	103.94	1,275	132,518	24,610	Sep 24 07:41 PM
Korenberg Matthew E	President & COO	Sep 23 '24	Option Exercise	52.72	9,772	515,227	60,549	Sep 24 07:41 PM
Korenberg Matthew E	President & COO	Sep 20 '24	Option Exercise	49.99	4,982	249,050	57,052	Sep 24 07:41 PM
Korenberg Matthew E	President & COO	Sep 23 '24	Sale	101.22	9,772	989,121	50,777	Sep 24 07:41 PM
Korenberg Matthew E	President & COO	Sep 20 '24	Sale	104.10	6,275	653,238	50,777	Sep 24 07:41 PM
Reardon Andrew	Officer	Sep 23 '24	Proposed Sale	99.60	2,000	199,201		Sep 23 05:30 PM
Korenberg Matthew E	Officer	Sep 23 '24	Proposed Sale	101.50	14,437	1,465,403		Sep 23 05:27 PM
Korenberg Matthew E	Officer	Sep 20 '24	Proposed Sale	104.10	6,275	653,238		Sep 20 06:12 PM
Espinoza Octavio	Officer	Sep 20 '24	Proposed Sale	103.94	1,275	132,518		Sep 20 05:39 PM
Espinoza Octavio	Chief Financial Officer	Sep 17 '24	Option Exercise	79.63	1,486	118,328	25,885	Sep 19 05:50 PM
Korenberg Matthew E	President & COO	Sep 16 '24	Option Exercise	58.49	5,774	337,696	54,008	Sep 18 07:55 PM
Espinoza Octavio	Chief Financial Officer	Aug 28 '24	Option Exercise	66.52	753	50,086	24,399	Aug 30 09:00 PM
Reardon Andrew	CLO & Secretary	Aug 28 '24	Option Exercise	52.27	1,500	78,405	24,034	Aug 30 08:56 PM
Reardon Andrew	CLO & Secretary	Aug 28 '24	Sale	106.39	1,500	159,591	22,534	Aug 30 08:56 PM
Reardon Andrew	Officer	Aug 28 '24	Proposed Sale	106.39	1,500	159,590		Aug 28 04:39 PM
Korenberg Matthew E	President & COO	Aug 26 '24	Sale	105.61	11,389	1,202,831	49,510	Aug 26 08:15 PM
Korenberg Matthew E	President & COO	Aug 23 '24	Sale	104.80	6,312	661,479	60,899	Aug 26 08:15 PM
Korenberg Matthew E	President & COO	Aug 22 '24	Sale	105.54	1,157	122,110	67,211	Aug 26 08:15 PM
Korenberg Matthew E	Officer	Aug 22 '24	Proposed Sale	105.03	18,858	1,980,567		Aug 22 06:05 PM
Korenberg Matthew E	President & COO	Aug 09 '24	Sale	98.50	18,245	1,797,132	68,368	Aug 13 05:21 PM
Davis Todd C	Chief Executive Officer	Aug 08 '24	Buy	97.39	2,500	243,480	123,010	Aug 09 05:52 PM
Korenberg Matthew E	Officer	Aug 09 '24	Proposed Sale	98.50	18,245	1,797,132		Aug 09 05:16 PM

Open in Screener

TECH

Bio-Techne Corp

Jul 11 • 04:00PM ET

54.14

Dollar change -0.27
Percentage change -0.50	%

Healthcare • Biotechnology • USA • NASD

Peers: TMO DHR ILMN A BIO QGEN NEO MTD

| Held by: VTI VOO VB RSP VBK SPY IVV XLV IBB IWR

Index	S&P 500	P/E	65.99	EPS (ttm)	0.82	Insider Own	1.13%	Shs Outstand	156.76M	Perf Week	1.88%
Market Cap	8.49B	Forward P/E	26.33	EPS next Y	2.06	Insider Trans	-0.92%	Shs Float	154.99M	Perf Month	5.33%
Enterprise Value	8.77B	PEG	6.60	EPS next Q	0.50	Inst Own	104.65%	Short Float	4.07%	Perf Quarter	0.13%
Income	131.65M	P/S	7.02	EPS this Y	7.27%	Inst Trans	3.94%	Short Ratio	2.72	Perf Half Y	-27.59%
Sales	1.21B	P/B	4.21	EPS next Y	8.31%	ROA	4.91%	Short Interest	6.32M	Perf YTD	-24.84%
Book/sh	12.87	P/C	60.34	EPS next 5Y	10.00%	ROE	6.53%	52W High	83.62 -35.25%	Perf Year	-24.06%
Cash/sh	0.90	P/FCF	38.45	EPS past 3/5Y	6.45% 11.13%	ROIC	5.42%	52W Low	46.01 17.67%	Perf 3Y	-40.31%
Dividend Est.	0.26 (0.47%)	EV/EBITDA	21.73	Sales past 3/5Y	7.58% 10.17%	Gross Margin	66.52%	Volatility	3.85% 3.75%	Perf 5Y	-19.75%
Dividend TTM	0.32 (0.59%)	EV/Sales	7.26	EPS Y/Y TTM	-35.33%	Oper. Margin	24.22%	ATR (14)	1.99	Perf 10Y	124.32%
Dividend Ex-Date	May 19, 2025	Quick Ratio	2.58	Sales Y/Y TTM	4.72%	Profit Margin	10.89%	RSI (14)	60.92	Recom	1.70
Dividend Gr. 3/5Y	0.00% 0.00%	Current Ratio	3.71	EPS Q/Q	-53.50%	SMA20	4.70%	Beta	1.39	Target Price	66.31
Payout	30.61%	Debt/Eq	0.21	Sales Q/Q	4.20%	SMA50	7.79%	Rel Volume	0.61	Prev Close	54.41
Employees	3100	LT Debt/Eq	0.20	Earnings	May 07 BMO	SMA200	-15.21%	Avg Volume	2.32M	Price	54.14
IPO	Feb 09, 1989	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.32% -0.32%	Trades		Volume	1,420,800	Change	-0.50%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-09-25	Initiated	TD Cowen	Buy	$65
May-30-25	Initiated	Wells Fargo	Overweight	$59
Apr-09-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Mar-18-25	Initiated	Evercore ISI	Outperform	$75
Feb-19-25	Downgrade	Robert W. Baird	Outperform → Neutral	$88 → $68
May-22-24	Downgrade	Citigroup	Buy → Neutral	$85
Feb-08-24	Initiated	Scotiabank	Sector Outperform	$80
Feb-02-24	Downgrade	Stifel	Buy → Hold	$65
Dec-07-23	Initiated	UBS	Buy	$80
Aug-28-23	Initiated	William Blair	Outperform
Jan-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight	$90
Dec-14-22	Initiated	Deutsche Bank	Buy	$100
Dec-12-22	Upgrade	Citigroup	Neutral → Buy	$81.25 → $100
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform	$89
Aug-25-22	Initiated	Credit Suisse	Outperform	$465
Apr-25-22	Downgrade	Wells Fargo	Equal Weight → Underweight	$370
Sep-15-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$600
Mar-08-21	Upgrade	Stephens	Equal-Weight → Overweight	$380 → $425
Feb-23-21	Upgrade	Stifel	Hold → Buy	$435
Jan-25-21	Reiterated	The Benchmark Company	Buy	$320 → $410

Show Previous Ratings

Jul-09-25 01:33AM	5 Revealing Analyst Questions From Bio-Techne's Q1 Earnings Call (StockStory)
Jun-30-25 08:49AM	Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock (Zacks)
Jun-25-25 04:46PM	Bio-Techne, USP Partner to Enhance Monoclonal Antibody, Gene Therapy Development (Insider Monkey)
08:44AM	Is Bio-Techne Stock Underperforming the Nasdaq? (Barchart)
Jun-24-25 07:00AM	Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development (PR Newswire)
01:15PM	Loading…
Jun-10-25 01:15PM	TECH Q1 Earnings Call: Management Highlights Market Uncertainties and Strategic Mitigation Efforts (StockStory)
07:00AM	ScaleReady Announces a G-Rex Grant has been awarded to Immuneel Therapeutics (PR Newswire)
Jun-06-25 04:08PM	Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector? (MarketWatch)
11:31AM	Why Is Techne (TECH) Down 3% Since Last Earnings Report? (Zacks)
Jun-02-25 11:33PM	Spotting Winners: Bio-Techne (NASDAQ:TECH) And Research Tools & Consumables Stocks In Q1 (StockStory)
May-30-25 12:47AM	Bio-Techne Corporation (TECH): A Bull Case Theory (Insider Monkey)
May-29-25 08:47AM	Is Bio-Techne Stock the Right Pick for Your Portfolio Now? (Zacks)
07:00AM	Bio-Techne to Present at Investor Conferences (PR Newswire)
May-14-25 04:54PM	S&P 500 Gains & Losses Today: Supermicro Stock Surges After DataVolt Deal (Investopedia) -7.27%
11:00AM	What Makes Bio-Techne Corporation (TECH) a Compelling Addition? (Insider Monkey)
07:00AM	Loading…
07:00AM	ScaleReady awards multiple G-Rex Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA) (PR Newswire)
May-12-25 07:00AM	Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025 (PR Newswire) +7.93%
May-10-25 11:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-08-25 09:30AM	Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing (PR Newswire)
07:00AM	Bio-Techne to Present at the BofA Securities 2025 Health Care Conference (PR Newswire)
03:16AM	Bio-Techne Corp (TECH) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amid Global ... (GuruFocus.com)
01:44AM	Q3 2025 Bio-Techne Corp Earnings Call (Thomson Reuters StreetEvents)
May-07-25 04:09PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
10:40AM	Bio-Techne outlines 2025 growth drivers with NIH uncertainty and strong Protein Sciences performance (Seeking Alpha)
10:38AM	Bio-Techne Corporation (TECH) Q3 2025 Earnings Call Transcript (Seeking Alpha)
10:05AM	Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket (Zacks)
09:54AM	Bio Techne (TECH) Fell on Negative Funding Environment (Insider Monkey)
09:30AM	Techne (TECH) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:34AM	Is the Options Market Predicting a Spike in BioTechne Stock? (Zacks)
07:40AM	Techne (TECH) Q3 Earnings and Revenues Beat Estimates (Zacks)
06:30AM	Loading…
06:30AM	BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS (PR Newswire)
06:30AM	BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM (PR Newswire)
May-06-25 07:00AM	ScaleReady awards a $300,000 G-Rex Grant to A2 Biotherapeutics, Inc. (PR Newswire)
May-05-25 10:00AM	Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline (Zacks)
May-02-25 07:54AM	Should You Hold Bio-Techne Corp. (TECH) For the Long Term? (Insider Monkey)
May-01-25 08:25AM	Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates (Zacks)
Apr-30-25 10:01AM	Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
07:51AM	TECH Gears Up to Report Q3 Earnings: Here's What to Expect (Zacks)
Apr-29-25 07:00AM	ScaleReady Announces March Biosciences as Recipient of G-Rex Grant to Advance Manufacturing of Novel CAR-T Cell Therapy (PR Newswire)
Apr-24-25 09:45AM	Aristotle Focus Growth Q1 2025 Commentary (Seeking Alpha)
09:09AM	Bio-Techne Corporation (TECH) Slid Due to NIH's Funding Concerns (Insider Monkey)
07:00AM	Bio-Techne Announces Early Access Program for Next-Generation Spatial Protein Proximity Detection (PR Newswire)
Apr-23-25 07:00AM	Bio-Techne to Showcase Cutting-Edge Solutions at the 2025 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Apr-21-25 08:00AM	OmniAb Announces Two New Appointments to its Board of Directors (Business Wire)
Apr-15-25 07:00AM	Bio-Techne to Host Conference Call on May 7, 2025, to Announce Third Quarter Fiscal 2025 Financial Results (PR Newswire)
Apr-14-25 02:09PM	Aristotle Large Cap Growth Q1 2025 Commentary (Seeking Alpha)
Apr-11-25 11:20AM	Novavax slides after RFK Jr. casts doubts about COVID vaccine (TipRanks)
Apr-10-25 01:32PM	Analyst Report: Bio-Techne Corporation (Morningstar Research) -8.90%
08:40AM	Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength? (Zacks)
Apr-09-25 09:46AM	Apple, Starbucks upgraded: Wall Street's top analyst calls (The Fly) +10.78%
Apr-08-25 06:49PM	Analyst Report: Bio-Techne Corporation (Morningstar Research) -6.69%
Apr-03-25 10:03AM	Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks) -6.03%
Apr-02-25 07:00AM	Leica Biosystems and Bio-Techne Expand Partnership to Enable Protease-Free Workflows for Automated Spatial Multiomics on the BOND RX Research Staining Instrument (PR Newswire)
Mar-31-25 10:00AM	Bio-Techne Opens New Customer Experience Centre in Germany (Zacks)
05:12AM	3 Reasons to Avoid TECH and 1 Stock to Buy Instead (StockStory)
Mar-28-25 05:06AM	Research Tools & Consumables Stocks Q4 Earnings: Bio-Techne (NASDAQ:TECH) Best of the Bunch (StockStory)
Mar-26-25 11:10AM	Columbia Acorn Fund Q4 2024 Commentary (SeekingAlpha)
07:00AM	Bio-Techne Announces New Customer Experience Centre in Dsseldorf, Germany (PR Newswire)
Mar-24-25 07:00AM	Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting (PR Newswire)
Mar-17-25 05:09AM	Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks (StockStory)
Mar-12-25 05:03AM	Q4 Earnings Highlights: Sotera Health Company (NASDAQ:SHC) Vs The Rest Of The Research Tools & Consumables Stocks (StockStory)
05:01AM	Research Tools & Consumables Stocks Q4 Recap: Benchmarking Bruker (NASDAQ:BRKR) (StockStory)
Mar-10-25 07:00AM	Bio-Techne Begins Shipping Leo - A Next Generation High-Throughput Simple Western System (PR Newswire)
Mar-07-25 11:31AM	Techne (TECH) Down 15.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-05-25 04:02AM	Q4 Earnings Highlights: Thermo Fisher (NYSE:TMO) Vs The Rest Of The Research Tools & Consumables Stocks (StockStory)
Mar-04-25 04:02AM	Unpacking Q4 Earnings: Danaher (NYSE:DHR) In The Context Of Other Research Tools & Consumables Stocks (StockStory)
Mar-03-25 07:00AM	Bio-Techne Launches New Panel Resolving Hard-to-Decipher Carrier Screening Genes (PR Newswire)
04:03AM	Winners And Losers Of Q4: Revvity (NYSE:RVTY) Vs The Rest Of The Research Tools & Consumables Stocks (StockStory)
Feb-28-25 08:36AM	Weitz Partners III Opportunity Fund Added Bio-Techne Corporation (TECH) to its Portfolio (Insider Monkey)
Feb-27-25 07:00AM	Bio-Techne to Present at Investor Conferences (PR Newswire)
Feb-20-25 07:00AM	Bio-Techne Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial Biology (PR Newswire)
Feb-18-25 07:00AM	Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System (PR Newswire)
Feb-10-25 07:19PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
Feb-06-25 02:09AM	Bio-Techne Corp (TECH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
12:40AM	Q2 2025 Bio-Techne Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-05-25 08:18PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
08:13AM	Illumina (ILMN) Reports Earnings Tomorrow: What To Expect (StockStory)
06:41AM	Bio-Techne (NASDAQ:TECH) Surprises With Strong Q4, Stock Soars (StockStory)
06:30AM	Bio-Techne Releases Second Quarter Fiscal 2025 Results (PR Newswire)
06:30AM	Bio-Techne Declares Dividend (PR Newswire)
Feb-04-25 07:00AM	Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors (PR Newswire)
Jan-21-25 07:00AM	ScaleReady Announces a G-Rex Grant has been awarded to BrainChild Bio (PR Newswire)
07:00AM	Bio-Techne to Host Conference Call on February 5, 2025, to Announce Second Quarter Fiscal 2025 Financial Results (PR Newswire)
Jan-10-25 07:00AM	Bio-Techne Expands RandD Systems AI-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine (PR Newswire)
07:00AM	Bio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine (PR Newswire)
Jan-08-25 07:00AM	ScaleReady Announces a G-Rex Grant has been awarded to Seattle Children's Therapeutics (PR Newswire)
07:00AM	BIO-TECHNE TO PRESENT AT PHACILITATE ADVANCED THERAPIES WEEK 2025 (PR Newswire)
Jan-07-25 07:00AM	BIO-TECHNE SUCCESSFUL ON SECOND CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC (PR Newswire)
Dec-20-24 07:00AM	BIO-TECHNE TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE (PR Newswire)
Dec-19-24 07:00AM	BIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENT (PR Newswire)
Dec-18-24 07:00AM	ScaleReady awards a G-Rex Grant to Moonlight Bio (PR Newswire) -5.13%
Dec-12-24 07:00AM	BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH MEDSANTEK TO EXPAND ACCESS TO PORTFOLIO ACROSS TURKEY (PR Newswire)
Dec-10-24 07:00AM	BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY (PR Newswire)
Dec-09-24 07:33PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
Nov-29-24 11:32AM	Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-27-24 07:00AM	BIO-TECHNE TO PRESENT AT THE CITI 2024 GLOBAL HEALTHCARE CONFERENCE (PR Newswire)
Nov-25-24 09:02AM	Gemini Bioproducts, LLC Acquires Selected Fetal Bovine Serum (FBS) Product Rights and Inventory from Bio-Techne (PR Newswire)
Nov-22-24 09:00AM	OverT Bio Receives $120K G-Rex Grant to Propel Solid Tumor Cell Therapy Advancements (Business Wire)
Nov-20-24 07:00AM	BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES (PR Newswire)
Nov-18-24 07:00AM	BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH (PR Newswire)

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Herr Amy E.	Director	Jun 09 '25	Option Exercise	44.33	1,280	56,742	3,256	Jun 11 04:20 PM
Herr Amy E.	Director	Jun 09 '25	Sale	49.77	1,280	63,705	1,976	Jun 11 04:20 PM
JOSHUA MOLHO	Officer	Jun 09 '25	Proposed Sale	49.77	1,280	63,705		Jun 09 04:19 PM
HIGGINS JOHN L	Director	May 01 '25	Option Exercise	21.84	12,000	262,080	60,196	May 05 04:18 PM
Bohnen Shane	SVP - General Counsel	Apr 03 '25	Option Exercise	0.00	2,260	0	3,941	Apr 07 04:25 PM
Herr Amy E.	Director	Feb 14 '25	Option Exercise	44.33	1,976	87,596	3,836	Feb 18 04:49 PM
Herr Amy E.	Director	Feb 14 '25	Sale	65.96	1,860	122,691	1,976	Feb 18 04:49 PM
JOSHUA MOLHO	Domestic Partner of Director	Feb 14 '25	Proposed Sale	65.96	1,860	122,691		Feb 14 04:08 PM
McManus Matthew	President - DGS	Feb 01 '25	Option Exercise	0.00	4,620	0	4,620	Feb 04 05:31 PM
Geist William	PRESIDENT, PROTEIN SCIENCES	Feb 01 '25	Option Exercise	0.00	3,320	0	14,401	Feb 04 05:27 PM
Kelderman Kim	Chief Executive Officer	Jan 27 '25	Option Exercise	37.70	13,392	504,878	52,396	Jan 29 04:35 PM
Kelderman Kim	Chief Executive Officer	Jan 27 '25	Sale	77.29	13,392	1,035,013	39,004	Jan 29 04:35 PM
KIM KELDERMAN	Director	Jan 27 '25	Proposed Sale	77.05	13,392	1,031,854		Jan 27 04:24 PM
Geist William	PRESIDENT, PROTEIN SCIENCES	Nov 01 '24	Option Exercise	0.00	9,912	0	14,351	Nov 05 04:48 PM
Hippel James	CFO	Nov 01 '24	Option Exercise	0.00	13,159	0	113,085	Nov 05 04:46 PM
HIGGINS JOHN L	Director	Sep 12 '24	Option Exercise	22.95	6,000	137,700	48,608	Sep 16 04:18 PM
Kelderman Kim	Chief Executive Officer	Aug 29 '24	Option Exercise	66.97	1,492	99,919	41,434	Sep 03 04:05 PM
Bohnen Shane	SVP - General Counsel	Aug 15 '24	Option Exercise	0.00	49	0	1,696	Aug 19 05:28 PM
BAUMGARTNER ROBERT V	Director	Aug 08 '24	Option Exercise	22.95	16,000	367,200	59,401	Aug 12 04:08 PM
BAUMGARTNER ROBERT V	Director	Aug 08 '24	Sale	72.10	16,000	1,153,664	43,401	Aug 12 04:08 PM
ROBERT V. BAUMGARTNER	Director	Aug 08 '24	Proposed Sale	72.10	16,000	1,153,664		Aug 08 04:13 PM
Hippel James	CFO	Aug 02 '24	Option Exercise	31.26	53,000	1,656,780	136,002	Aug 06 04:23 PM
Kelderman Kim	Chief Executive Officer	Jul 31 '24	Option Exercise	37.70	14,000	527,800	49,421	Aug 02 04:17 PM
Hippel James	CFO	Jul 23 '24	Option Exercise	31.26	35,000	1,094,100	107,284	Jul 25 04:31 PM

OABI

OmniAb Inc

LGND

Ligand Pharmaceuticals, Inc

TECH

Bio-Techne Corp

Upgrade your FINVIZ experience